Utama › Kanser Payudara › Arizona › Phoenix
Kajian klinikal Kanser Payudara di Phoenix, AZ
25 kajian untuk Kanser Payudara sedang mencari peserta di lokasi dalam dan sekitar Phoenix (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Cancer Center at Saint Joseph's, Phoenix
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Mengambil pesertaFasa 2
- Mayo Clinic Hospital, Phoenix
PRE-ISPY Phase I/II Oncology Platform Program
Mengambil pesertaFasa 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Mengambil pesertaFasa 3
- Ironwood Cancer & Research Centers, Phoenix
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Mengambil pesertaFasa 2
- Mayo Clinic Building-Phoenix, Phoenix
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Mengambil pesertaFasa 3
- Mayo Clinic Cancer Center ( Site 0034), Phoenix
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Mengambil peserta
- Mayo Clinic Arizona, Phoenix
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Mengambil pesertaFasa 3
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Mengambil pesertaFasa 2
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Mengambil pesertaFasa 3
- Banner University Medical Center - Phoenix Campus (Banner Good Samaritan Medical Center), Phoenix
Breast Cancer, Reasoning, and Activity Intervention
Mengambil peserta
- Mayo Clinic in Arizona, Phoenix
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Mengambil pesertaFasa 3
- The Dignity Health Cancer Institute, Phoenix
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Mengambil pesertaFasa 3
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Mengambil pesertaFasa 3
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Mengambil pesertaFasa 3
- Mayo Clinic Hospital in Arizona, Phoenix
E-Mindfulness Approaches for Living After Breast Cancer
Mengambil pesertaFasa 3
- Mayo Clinic Hospital in Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Mengambil pesertaFasa 1/2
- USOR HonorHealth, Phoenix
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Mengambil pesertaFasa 3
- Ironwood Cancer & Research Centers, Phoenix
The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors
Mengambil peserta
- Arizona State University, Phoenix
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Mengambil pesertaFasa 3
- Cancer Center at Saint Joseph's, Phoenix
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Mengambil pesertaFasa 1/2
- Mayo Clinic, Phoenix
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Cancer Center at Saint Joseph's, Phoenix
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Vincere Cancer Center, Phoenix
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Mengambil pesertaKajian pemerhatian
- Arizona Oncology Associates, PC, Phoenix
Kajian Kanser Payudara di bandar lain
- New York City, NY136 kajian
- Houston, TX126 kajian
- Boston, MA112 kajian
- Nashville, TN81 kajian
- Los Angeles, CA73 kajian
- Edison, NJ68 kajian
- St. Louis, MO64 kajian
- Queens, NY64 kajian
- Durham, NC64 kajian
- Chicago, IL59 kajian
- Philadelphia, PA56 kajian
- Dallas, TX55 kajian
Kajian lain di Phoenix
- Kanser Kolorektal25 kajian
- Obesiti22 kajian
- Kanser Metastatik20 kajian
- Kanser Paru-paru Bukan Sel Kecil20 kajian
- Kegagalan Jantung18 kajian
- Kanser (semua jenis)17 kajian
- Kanser Prostat17 kajian
- Penyakit Kardiovaskular16 kajian
- Mieloma Pelbagai16 kajian
- Kanser Pankreas16 kajian
- Berat Badan Berlebihan15 kajian
- Penyakit Alzheimer15 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.